Preventing Pneumococcal Disease among Infants and Young Children. Recommendationsof the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, Vol. 49, No. RR-9, October 6, 2000. Recommendations and Reports

摘要

In February 2000, a 7-valent pneumococcal polysaccharide-protein conjugatevaccine (Prevnar, marketed by Wyeth Lederle Vaccines) was licensed for use among infants and young children. CDCs Advisory Committee on Immunization Practices (ACIP) recommends that the vaccine be used for all children aged 223 months and for children aged 2459 months who are at increased risk for pneumococcal disease (e.g., children with sickle cell disease, human immunodeficiency virus infection, and other immunocompromising or chronic medical conditions). ACIP also recommends that the vaccine be considered for all other children aged 2459 months, with priority given to (1) children aged 2435 months, (2) children who are of Alaska Native, American Indian, and African-American descent, and (3) children who attend group day care centers. This report includes ACIPs recommended vaccination schedule for infants at ages 2, 4, 6, and 1215 months. This report also includes a pneumococcal vaccination schedule for infants and young children who are beginning their vaccination series at an older age and for those who missed doses. In addition, this report updates earlier recommendations for use of 23-valent pneumococcal polysaccharide vaccine among children 2 years. Among children aged 2459 months for whom polysaccharide vaccine is already recommended, ACIP recommends vaccination with the new conjugate vaccine 2 months later, by 23-valent polysaccharide vaccine. Conjugate vaccine has not been studied sufficiently among older children or adults to make recommendations for its use among persons 5 years. Persons 5 years who are at increased risk for serious pneumococcal disease should continue to receive 23-valent polysaccha-ride vaccine in accordance with previous ACIP recommendations.